Connect your AI

Citius Oncology, Inc. CTOR Gross Product Revenue

Other financials

Income statement

Revenue$1.7M—

Gross profit$1.3M—

Operating income-$28.6M-283%

Net income-$26.6M-244%

EPS (diluted)-$0.27-145%

Balance sheet

Cash & equivalents$2.6M+2,350,466%

Total equity$35.3M-1.0%

Total assets$100.7M+10.1%

Cash flow

Operating cash flow-$3.8M-179%

Valuation

Market cap$60.45M-74.7%

Returns & leverage

Return on equity-119.9%+46.7pp

Current ratio0.5×+0.1×

Where this comes from

Reported directly by Citius Oncology, Inc. in its filing.

Tagged under the XBRL concept ctor:GrossProductRevenue.

The official record: Citius Oncology, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about Citius Oncology, Inc.'s gross product revenue.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Citius Oncology, Inc.'s gross product revenue?: Citius Oncology, Inc. (CTOR) reported gross product revenue of $2M in Q1 2026.